Measuring drug exposure: concordance between defined daily dose and days' supply depended on drug class.
Sinnott, Sarah-Jo;
Polinski, Jennifer M;
Byrne, Stephen;
Gagne, Joshua J;
(2015)
Measuring drug exposure: concordance between defined daily dose and days' supply depended on drug class.
Journal of clinical epidemiology, 69.
pp. 107-113.
ISSN 0895-4356
DOI: https://doi.org/10.1016/j.jclinepi.2015.05.026
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
OBJECTIVES: To determine the concordance between two methods to measure drug exposure duration from pharmacy claim data. STUDY DESIGN AND SETTING: We conducted a cohort study using 2002-2007 US Medicaid data. Initiators of eight drug groups were identified: statins, metformin, atypical antipsychotics, warfarin, proton pump inhibitors (PPIs), angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (ns-NSAIDs), and coxibs. For each patient, we calculated two measures of exposure duration using (1) observed days' supply available in US pharmacy claims and (2) the World Health Organisation's Defined Daily Dose (DDD) methodology. We used Wilcoxon signed rank tests to compare medians and Spearman correlations to assess correlation between the two measures. RESULTS: Cohort sizes ranged from 143,885 warfarin users to >3,000,000 ns-NSAID users. Similar median exposure durations were observed for ACE inhibitors (70 days vs.75 days), PPIs (44 days vs. 45 days), and coxibs (44 days vs. 45 days). The DDD method overestimated exposure duration for ns-NSAIDs and underestimated for the remaining drug groups, relative to days' supply. Spearman correlation coefficients ranged from 0.2 to 0.8. CONCLUSION: Using DDDs to estimate drug exposure duration can result in misclassification. The magnitude of this misclassification might depend on doses used which can vary according to factors such as local prescribing practices, renal function, and age.